Sunitinib Newbury 50 mg Norge - norsk - Statens legemiddelverk

sunitinib newbury 50 mg

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg

Sunitinib Newbury 12.5 mg Norge - norsk - Statens legemiddelverk

sunitinib newbury 12.5 mg

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 12.5 mg

Sunitinib Newbury 25 mg Norge - norsk - Statens legemiddelverk

sunitinib newbury 25 mg

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 25 mg

Pirfenidone Newbury 267 mg Norge - norsk - Statens legemiddelverk

pirfenidone newbury 267 mg

newbury pharmaceuticals ab - pirfenidon - tablett, filmdrasjert - 267 mg

Pirfenidone Newbury 801 mg Norge - norsk - Statens legemiddelverk

pirfenidone newbury 801 mg

newbury pharmaceuticals ab - pirfenidon - tablett, filmdrasjert - 801 mg

Icatibant Newbury 30 mg Norge - norsk - Statens legemiddelverk

icatibant newbury 30 mg

newbury pharmaceuticals ab - ikatibantacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 30 mg

Lapatinib Newbury 250 mg Norge - norsk - Statens legemiddelverk

lapatinib newbury 250 mg

newbury pharmaceuticals ab - lapatinib ditosylatmonohydrat - tablett, filmdrasjert - 250 mg

Solifenacin/Tamsulosin Newbury 6 mg / 0.4 mg Norge - norsk - Statens legemiddelverk

solifenacin/tamsulosin newbury 6 mg / 0.4 mg

newbury pharmaceuticals ab - solifenacinsuksinat / tamsulosinhydroklorid - tablett med modifisert frisetting - 6 mg / 0.4 mg

Dasatinib Accordpharma Den europeiske union - norsk - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Rivastigmine 1 A Pharma Den europeiske union - norsk - EMA (European Medicines Agency)

rivastigmine 1 a pharma

1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatisk behandling av mild til moderat alvorlig alzheimers demens. symptomatisk behandling av mild til moderat alvorlig demens hos pasienter med parkinsons sykdom.